Health and Fitness Health and Fitness
Thu, February 23, 2012
[ Thu, Feb 23rd 2012 ] - Market Wire
Cigna Corporation Announces Appearance at the Citi 2012 Global Health Care Conference
[ Thu, Feb 23rd 2012 ] - Market Wire
Abbott Collaborates with Leading U.S. Forensics Center on Human Identification Testing
[ Thu, Feb 23rd 2012 ] - Market Wire
Medtronic CFO Gary Ellis to Speak at Citi Healthcare Conference
[ Thu, Feb 23rd 2012 ] - Market Wire
Theratechnologies to Present at RBC Capital Markets Conference
[ Thu, Feb 23rd 2012 ] - Market Wire
OPKO Health to Present at the Citi 2012 Global Health Care Conference
[ Thu, Feb 23rd 2012 ] - Market Wire
Hospira Joins the Generic Pharmaceutical Association
[ Thu, Feb 23rd 2012 ] - Market Wire
Amarantus BioSciences to Present at the 2012 Nati .. ent Banking Association Conference in New Orleans
[ Thu, Feb 23rd 2012 ] - Market Wire
BIOLASE and Cefla Dental Group Announce Exclusive Distribution Agreement
[ Thu, Feb 23rd 2012 ] - Market Wire
A Forward Look, the Year Ahead - Featured Researc .. n AngioDynamics, Inc. and Kensey Nash Corporation
[ Thu, Feb 23rd 2012 ] - Market Wire
Cytori to Webcast Year End Financial Results March 8
[ Thu, Feb 23rd 2012 ] - Market Wire
SecureAlert, Inc. Reports Record Monitoring Revenues
[ Thu, Feb 23rd 2012 ] - Market Wire
MelaFind(R) Results Improve Detection of Melanoma, Study Shows
[ Thu, Feb 23rd 2012 ] - Market Wire
Rigel Announces Participation at Two Investor Conferences
[ Thu, Feb 23rd 2012 ] - Market Wire
PROLOR Biotech to Present Preclinical Data on Its .. ors VIIa and IX at European Hemophilia Conference
[ Thu, Feb 23rd 2012 ] - Market Wire
Theragenics Reports Revenue & Earnings for Fourth Quarter & Year-End 2011
[ Thu, Feb 23rd 2012 ] - Market Wire
Implant Sciences' Quantum Sniffer Explosives and .. Be Exhibited at Security Trade Show in Madrid, Sp
[ Thu, Feb 23rd 2012 ] - Market Wire
Mylan Receives Tentative FDA Approval Through PEPFAR for Pediatric HIV/AIDS Therapy
[ Thu, Feb 23rd 2012 ] - Market Wire
Nuvo Research provides an update on its Pennsaid franchise
[ Thu, Feb 23rd 2012 ] - Market Wire
MAP Pharmaceuticals Issued Additional U.S. Patent .. id Treatment of Migraine Based Upon Pharmacokinet
[ Thu, Feb 23rd 2012 ] - Market Wire
Teleflex Introduces the FloCath Quicka" Female Catheter and Insertion Kit
[ Thu, Feb 23rd 2012 ] - Market Wire
PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
Wed, February 22, 2012
[ Wed, Feb 22nd 2012 ] - Market Wire
Auxilium Pharmaceuticals, Inc. and Actelion Pharm .. boration Agreement for XIAFLEX in Canada, Austral
[ Wed, Feb 22nd 2012 ] - Market Wire
Dendreon Announces New Time for Fourth Quarter an .. Conference Call and Webcast Presentations at Upco
[ Wed, Feb 22nd 2012 ] - Market Wire
Health Net of California Earns NCQA Multicultural .. for Its Commercial and Medicaid Lines of Business
[ Wed, Feb 22nd 2012 ] - Market Wire
Director Ann C. Berzin Opts to Not Stand for Re-Election to Kindred Healthcare Board of Directors
[ Wed, Feb 22nd 2012 ] - Market Wire
Ongoing Training Benefits ZYTO Healthcare Professional Customers
[ Wed, Feb 22nd 2012 ] - Market Wire
Leisureworld Senior Care Corporation Reports 2011 Fourth Quarter and Year End Financial Results
[ Wed, Feb 22nd 2012 ] - Market Wire
Sequenom, Inc. Files Motion for Preliminary Injunction Against Aria Diagnostics
[ Wed, Feb 22nd 2012 ] - Market Wire
FDA Advisory Committee Recommends Approval of Qnexa
[ Wed, Feb 22nd 2012 ] - Market Wire
Medivation Announces Fourth Quarter and Year-End .. ncial Results Teleconference on February 29, 2012

Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012


Published on 2012-02-22 14:32:48 - Market Wire
  Print publication without navigation


February 22, 2012 17:26 ET

Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012

SAN FRANCISCO, CA--(Marketwire - Feb 22, 2012) - Medivation, Inc. (NASDAQ: [ MDVN ]) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end financial results and provide a general business update on Wednesday, February 29, 2012 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2011 will be released after markets close on February 29, 2012.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug MDV3100 in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at [ www.medivation.com ].


Contributing Sources